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Abstract
The observational studies of hormone users are compromised by systematic biases that lead
to an overestimation of benefit and an underestimation of risk. Studies of mechanism could
support either benefit or harm. The results of clinical trials of oral hormone therapy in women
with existing coronary heart disease (CHD) have been uniformly disappointing. The largest
trial found an early increased risk for CHD and for venous thromboembolism.
Postmenopausal hormone therapy should not be considered for CHD prevention until
methods for excluding high-risk women have been established, and until the results of the
long-term trials have shown benefit. There is a need for clinical trials of nonoral estrogens.
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Introduction
The conventional wisdom that postmenopausal hormone
therapy reduces the risk for CHD is being questioned, fol-
lowing reports from clinical trials that have failed to show
benefit, or have even produced evidence of increased risk
during the first years of treatment. The Heart and Estrogen/
progestin Replacement Study [1] was a 4.1-year sec-
ondary prevention trial of conjugated equine estrogens
plus medroxyprogesterone in 2763 women with an intact
uterus, and its finding of increased risk during the first year
with possible subsequent benefit is consistent with an
cohort study of women with prior heart disease from the
Nurses’ Health Study [2]. The Estrogen Replacement and
Atherosclerosis trial [3] was an angiographic trial of 309
women who were randomized to conjugated equine estro-
gens, conjugated equine estrogens plus medroxyproges-
terone, or placebo. At the end of 3 years there was no dif-
ference in angiographic progression between the study
groups. Despite these findings, it remains possible that
longer term treatment will reduce the risk for CHD. Even if
that is so, the apparent excess early risk needs to be
explained and methods found to avoid it, if post-
menopausal hormone therapy is to regain its position as a
recommended preventive treatment for CHD.
The most convincing strands of evidence in humans that
estrogen may prevent CHD comes from observational epi-
demiology and from studies of mechanism. Each type of
evidence has strengths and weaknesses, and is subject to
varying interpretations.Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 3 Rossouw
Observational epidemiology
The later onset of CHD in women than in men may be due
to higher endogenous estrogen levels (and consequently
higher high-density lipoprotein [HDL]-cholesterol levels) in
premenopausal women than in men. However, the HDL-
cholesterol difference between women and men is an
androgen effect, not an estrogen effect. Up to puberty,
young men and women have similar HDL-cholesterol
levels. At puberty, concurrent with the rise in endogenous
testosterone levels, the HDL-cholesterol levels in young
men decline to the lower adult level [4,5]. A 20% differ-
ence in HDL-cholesterol levels predicts at least a 20% dif-
ference in CHD rates in the short term, and may predict
even larger differences in CHD rates over a lifetime [6].
Thus, the entire sex difference in CHD risk may be due to
the lifelong difference in HDL-cholesterol levels.
It is often stated that CHD rates in women rise steeply
after the menopausal age, and that this is again due to the
relatively lower levels of estrogen in postmenopausal
women. However, there is actually no evidence for an
increase in the year-on-year incidence of CHD around the
age of menopause. The linear relationship between age
and CHD incidence as seen on a semilogarithmic plot
shows that there is a constant proportional increase in
CHD incidence with age, with no inflection upward at the
average age of menopause [7]. This is strong evidence for
an age effect, and evidence against an effect of
menopause. The Nurses’ Health Study investigators [8]
reported that, after controlling for age and smoking status,
the natural menopause is not associated with an
increased risk for CHD. Those investigators also reported
that, in contrast to the natural menopause, bilateral
oophorectomy is associated with an increased risk for
CHD in women who had never taken estrogen after
menopause. However, that study had very few cases of
CHD in women with oophorectomy, and the increased risk
was no longer significant in the multivariate analysis. The
use of estrogens appeared to eliminate this increased risk.
Even if these findings were real, it is possible that women
who have a hysterectomy and bilateral oophorectomy are
at higher risk because of a higher prevalence of metabolic
risk factors such as central obesity, high blood pressure,
lipid disorders, and glucose intolerance. The finding of an
apparently lower risk in women who subsequently used
estrogen would be subject to a number of biases (dis-
cussed below).
By far the most persuasive evidence in favor of a protec-
tive effect for estrogen comes from the large number of
cohort studies that compared CHD risk in post-
menopausal women currently using estrogen with that in
those who had never used estrogen. These studies have
shown consistently that CHD risk is 35–50% lower in
estrogen users, after adjusting for other risk factors [9].
The lower risk has been found in studies of estrogen
alone, as well as in studies of estrogen used in combina-
tion with a progestin. For healthy women, the lower risk is
found in those who have recently started estrogen, as well
as in long-term users [10].
These findings from observational epidemiology provide
the rationale for clinical trials testing whether and to what
degree current use of postmenopausal hormone therapy
prevents a first heart attack. However, observational epi-
demiology is not sufficient to prove the case, because
even the best studies may be subject to a variety of sys-
tematic biases that could lead to an overestimation of
benefit and an underestimation of harm from hormone
therapy, hence the need for an unbiased estimate from
clinical trials. These biases in observational studies are
summarized below.
Biases in observational studies
In combination, the biases summarized below will lead to a
systematic overestimation of benefit, and an underestima-
tion of risk. Adjusting for baseline differences in risk
factors will mitigate only one kind of bias (healthy user
selection bias), but will not affect compliance, surveillance,
or survivor bias. Thus, the real benefit for CHD may be
much less than that predicted by the observational
studies, or there may be no benefit at all. The clinical trials
to date have failed to show overall benefit for CHD over
the short term (although longer term trials are ongoing to
ascertain the long-term effects, particularly in women
without prevalent CHD).
Healthy user selection bias
Some, but not all studies have shown that women who
elect to use hormone therapy are healthier than those who
elect not to. Health differences may be present before
they commence therapy, and thus the more favorable
health outcome in hormone users may be due to the char-
acteristics of the women who take hormones, rather than
due to the intrinsic effects of hormones [11]. The differ-
ences in risk factors may be large, and in themselves
could explain a large part of the lower risk in hormone
users. The better observational studies adjusted for some
of these variables, but could not adjust for variables that
either were not measured at all, or were not measured
before the commencement of the hormone therapy.
Compliance bias
Women who use hormone therapy for a number of
years are a highly select group with good compliance.
Clinical trials of other preventive treatments (e.g. b-
blockers) have demonstrated that patients who are
good adherers to the study treatment (irrespective of
whether they are in the active or placebo arms) have up
to 60% reduced risk for death compared with poor
adherers [12]. This remarkable finding is due to the
characteristics of good adherers, who are likely to bec
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more aware of their health than are poor adherers, and
therefore will be taking a number of health-promoting
steps (either consciously or unconsciously), resulting in
a lower mortality. Compliance bias is very powerful, and
is impossible to correct for in an observational study.
The very definition of the index group of hormone users
in an observational study, especially in the case of
long-term current users, ensures that a very special
group is selected for study.
Surveillance bias
Since hormones are prescription drugs, women who use
them are more likely to be in contact with the medical care
system than are other women. This leads to a greater likeli-
hood that risk factors and early disease will be identified
and treated, thus lowering mortality from CHD. Reports
from the Nurses’ Health Study illustrate this surveillance
bias phenomenon. For each of CHD and stroke, current
hormone users have greater apparent risk reductions for
mortality than for incidence [10,13].
Survivor bias
Another type of bias that will ascribe a lower mortality to
current hormone users is the fact that women who stop
hormones often do so because of intercurrent illness.
Women who have recently stopped taking hormones have
a markedly higher total mortality, as well as cause-specific
mortality from cardiovascular disease and cancer [14].
Thus, the women who remain on hormones are survivors
with a lower mortality than women in the general popula-
tion. Like compliance bias, it is very difficult to correct for
survivor bias in an observational study.
Studies of mechanisms
The possibility that estrogen may reduce CHD risk has
stimulated a wide variety of studies that have attempted to
explain the presumed benefit. Because it was unexpected,
fewer studies have been done to explain the apparent
excess risk early during the course of treatment. Mecha-
nisms that may contribute to benefit include lowered low-
density lipoprotein cholesterol and lipoprotein(a) levels,
raised HDL-cholesterol levels, reduced fibrinogen levels
and enhanced fibrinolysis (reduced plasminogen activator-
inhibitor 1 and increased D-dimer levels), reduced homo-
cysteine levels, antioxidant properties, and improved
endothelial function (reduced E-selectin levels and
improved flow-mediated dilatation) [15]. On the other
hand, several mechanisms that might increase risk have
been found, including increases in triglycerides, in some
coagulation markers (eg factor VII, prothrombin fragments
1+2, activated protein C resistance), and in the inflamma-
tory marker C-reactive protein [16–18]. Particularly with
regard to coagulation and inflammation, laboratory mea-
surements do not predict whether the predominant effect
will be favorable or unfavorable. On the other hand,
studies of venous thromboembolism (including clinical
trials) provide unequivocal evidence that the overall effect
is indeed procoagulant [1,19].
Compounding this difficulty in interpreting laboratory mea-
surements is the fact that progestins counteract some of
the effects of estrogens, and that the clinical expression of
metabolic changes may be time dependent. The early
excess risk for arterial disease observed in Heart and
Estrogen/progestin Replacement Study [1] might have
been due to an initial procoagulant or inflammatory effect
on susceptible plaques, whereas the favorable effects in
the survivors might have been due to the later assertion of
the generally favorable lipid effects. The role of the direct
vascular effect of estrogen is unclear, because impaired
endothelial function has not yet been established as a risk
factor for CHD. Interestingly, current estrogen users do
not appear to have a lower risk for angina, as one would
expect if direct vascular effects were important [10].
Overall, the studies of mechanisms have not resolved the
core issue of whether estrogens protect against CHD.
It is important to realize that almost all of the studies of
mechanism were done using oral estrogen preparations,
and thus may have little relevance in explaining the sex dif-
ference in CHD. Ovarian estrogen directly enters the sys-
temic circulation, unlike oral estrogens, which undergo
first-pass hepatic circulation and which need to be given
at 10 times the dose of nonoral estrogen in order to
achieve similar blood levels. These doses of estrogens
cause changes in the hepatic metabolism of a variety of
proteins, including lipid apoproteins, coagulation proteins,
and (probably) C-reactive protein [20,21]. The large
effects on lipids and coagulation proteins described for
oral estrogens are greatly attenuated, absent, or in the
opposite direction with nonoral estrogens. Nonoral estro-
gens have very modest effects on lowering low-density
lipoprotein cholesterol and lipoprotein(a), they lower rather
than raise triglycerides, they have no effect on HDL-cho-
lesterol, and they have a modest or no effect on coagula-
tion protein levels [22–24]. Nonoral estrogens retain the
ability to improve endothelial function [25]. Additional
mechanistic studies, as well as epidemiologic studies and
clinical trials, that focus on the role of nonoral estrogen
preparations are needed.
Conclusion
Despite the substantial evidence suggesting benefit for
CHD, the trials of oral estrogens have failed thus far to
show benefit, and there are some suggestions of early
harm. These findings may be related to the new knowl-
edge that oral estrogens are prothrombotic. It is not
known whether the failure to show benefit in the short
term is due to the particular estrogen and estrogen/prog-
estin combination used in these trials, or will apply also to
other dosages and forms of oral estrogen and progestin,
and in particular whether it will apply to nonoral routes ofadministration. Postmenopausal hormone use should not
be considered for the prevention or treatment of CHD until
strategies to exclude women who are at high risk for early
events have been devised, and until the long-term clinical
trials have shown benefit for CHD. Hormones have multi-
ple effects on several organ systems, and the overall risk
and benefit depends greatly on whether a reduction in the
risk for CHD is realized. Therefore, it is critically important
that this issue is settled before recommending the use of
postmenopausal hormones for this indication.
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